Psilocybin (Usona Institute) for depression

Based on the public registry summary, this study is trying to understand: This study aims to investigate the effects of a single dose of psilocybin, delivered in the contextof pre- and post-dose psychotherapy, on symptoms of depression and burnout suffered by healthcare clinicians as a result of frontline work in the COVID pandemic. The study team can confirm the exact objective and what it means for you.

This appears to be a medication / drug study involving Psilocybin (Usona Institute), Active placebo. The listed phase is PHASE3. Ask the study team what that means in practice for safety, monitoring, and criteria.

This study may concern people with ptsd; age range: Over 18 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

The public registry appears to mention a loved one, caregiver, or family involvement. Ask whether that person must participate, provide information, attend visits, or simply be available if needed. The study team must confirm what is required.

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

This study is sponsored by University of Washington, which appears to be a university. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join. The registry lists an estimated enrollment of 30 participants.